ArticleInsights into imaging2025
Computed tomography radiomics to predict microsatellite instability status and immunotherapy response in gastric cancer.
Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiomics for Prediction of Microsatellite Instability Status in Gastric Cancer: A Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next-Generation Approaches.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Predicting response to neoadjuvant chemotherapy combined with immunotherapy in gastric cancer based on habitat imaging and peritumoral radiomics: a two-center study.Journal of translational medicine · 2026Article
- Radiogenomic landscape of the hallmarks of cancer.Biomarker research · 2026Review
- Early- and advanced-stage MSI-H non-colorectal cancers: best management and challenges in 2025.ESMO gastrointestinal oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesTo develop and validate a CT radiomics model for predicting microsatellite instability (MSI) status in preoperative gastric cancer (GC) patients and to explore the underlying immune infiltration pattern of the radiomics model. MATERIALS AND
methodsThis study used three retrospective datasets from Tongji Hospital (n = 304, training set), Xiangyang Central Hospital (n = 48, external testing set 1) and public datasets from The Cancer Imaging Archive (TCIA) (n = 43, external testing set 2). The preoperative contrast-enhanced CT images of GC were evaluated. Radiomics features were extracted and selected to construct the radiomics model in the training set, and further validated in the other two external testing sets. The outcome cohort, including 68 advanced unresectable GC patients receiving immunotherapy, was used to assess the predictive value of the radiomics model for treatment response and outcomes. We analyzed RNA-sequencing data from TCIA to investigate the underlying genomics characterization and immune infiltration spectrum of the radiomics model.
resultsFour radiomic features were ultimately selected to develop the radiomics model. The model demonstrated good predictive performance for MSI status, achieving AUCs of 0.952, 0.835, and 0.879 in the training set and the two external testing sets, respectively. Radiomics scores (Radscores) was an independent predictor for PFS in the outcome cohort (HR: 0.145; 95% CI: 0.032-0.657; p = 0.012). Radscores were positively correlated with CD8+ T cells (R = 0.74, p = 0.013) and negatively related to M2-type macrophages (R = -0.67, p = 0.028).
conclusionOur CT radiomics model could effectively predict MSI status and immunotherapy outcomes in GC patients therefore, may act as a potential noninvasive tool for personalized treatment decisions. CRITICAL RELEVANCE STATEMENT: Our study develops a noninvasive biomarker based on readily available imaging to identify gastric cancer patients who may benefit from immunotherapy. It also reveals biological meanings of the radiomics biomarker, promoting further research into interpretability and clinical application of radiomics. KEY POINTS: A CT-based radiomics model was constructed to noninvasively predict gastric cancer (GC) microsatellite instability status. This immune-related radiomics model can effectively predict immunotherapy outcomes in GC. This noninvasive method can serve as a supplement for treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.